The first Deloitte Access Economics Report on the
Economic analysis of motor neurone disease (MND) in Australia reveals that the total cost of MND in Australia was
$2.37 billion in 2015, comprising $430.9 million in economic costs and $1.94 billion in burden of disease costs. The report, commissioned by MND Australia, was officially launched at Parliament House, Canberra on
24 February 2016.
When you receive a diagnosis of MND, money is the last thing on your mind. But along with the relentless physical and emotional effects on yourself and loved ones are the financial costs: early retirement, medical appointments, hospitalisations, treatments, equipment, wheelchair transport, personal care ... There is support from the state MND associations and government, but it all adds up.
Kirsten Harley, MND NSW Board member living with MND
Let's talk about MND costs
Join in the conversation on our Facebook and Twitter pages using #MNDcosts and #MNDaction.
Download #MNDaction resources to support our social media campaign.
A STRONG VOICE FOR MND
On 24 February 2016, MND Australia, along with State MND Associations, MPs, Senators and key representatives from research, disability and palliative care attended the report launch and morning tea hosted by Alex Hawke MP at Parliament House, Canberra.
MND NSW Board Member
Kirsten Harley spoke about her experience of living with MND.
Watch Kirsten's powerful speech 'A Strong Voice for MND'
Facts at a Glance Infographic
/MND-in-Aust-A4-Front-(1).PNG.aspx "MND-in-Aust-A4-Front-(1).PNG")
/MND-in-Aust-A4-Back-(1).PNG.aspx?width=350&height=489 "MND-in-Aust-A4-Back-(1).PNG")
Download your copy of the latest infographic flyer
Report Citation
The Economic analysis of motor neurone disease in Australia report was written by Deloitte Access Economics. The report, or any findings from the report, should be referenced as follows;
"Deloitte Access Economics 2015, Economic analysis of motor neurone disease in Australia, report for Motor Neurone Disease Australia, Deloitte Access Economics, Canberra, November."
This report was prepared solely for the use of Motor Neurone Disease Australia. It is not intended to and should not be used or relied upon by anyone else and Deloitte Access Economics accepts no duty of care to any other person or entity. The report has been prepared to raise awareness of the impacts of MND and contribute to improving policy in this area. You should not refer to or use the Deloitte Access Economics name or the advice for any other purpose. The copyright of this report belongs to Deloitte Access Economics.
MEDIA ENQUIRIES
Media release
If you would like to organise an interview or produce a story about the Deloitte Access Economics Report,
Economic analysis of motor neurone disease in Australia, contact Rachel Rizk, 0414 219 015
rachelr@mndaust.asn.au; or Alison Mudie,
alisonm@mndaust.asn.au.
MND ACTION – MND AUSTRALIA CALLS ON THE GOVERNMENT TO:
Double investment in research
Invest at least $20 million annually in large research projects until researchers understand the causes of MND and find an effective treatment
Make MND a National Health Priority
Include progressive neurological diseases as a National Health Priority by 2017
Fast-track equal access to services and support
Ensure fast-track access to care and support services to meet the reasonable and necessary support needs of all people living with MND by June 2017
Ensure Information, Linkages and Capacity Building (ILC) funding for state MND associations to provide disease-specific and timely information, referral to the right service at the right time, ongoing support, cross sector collaboration and support for carers to delay the need for individually funded packages
Work with state MND associations to create cost-effective access to equipment and technology
Fund the full range of assistive technology as part of a person’s NDIS plan and aged care package, both now and as the NDIS rolls out nationally
Subsidise non-invasive ventilation in the management of MND